Carcinoid Tumor clinical trials

The registry lists 104 studies for Carcinoid Tumor across more than 10 countries. 11 are recruiting or about to start. 53 of them are mainly about Carcinoid Tumor (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its narrower condition Malignant Carcinoid Syndrome too: 105 studies, 11 open.

Get an email when these change. Save the Carcinoid Tumor studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 51
Status unknown: 12
Recruiting: 10
Terminated: 10
Active, not recruiting: 9
Withdrawn: 8

Phase

Phase 2: 49
Phase 1: 20
Phase 3: 9
Phase 4: 3
Early Phase 1: 2

Where

United States: 65
Canada: 15
France: 11
Italy: 8
Spain: 7
Poland: 7

Who runs them

Novartis Pharmaceuticals (8) · Dana-Farber Cancer Institute (7) · H. Lee Moffitt Cancer Center and Research Institute (4) · British Columbia Cancer Agency (4) · Suez Canal University (3) · M.D. Anderson Cancer Center (2) · RayzeBio, Inc. (2) · Hospices Civils de Lyon (2)

What is being tested here

Drugs under test in Carcinoid Tumor studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Everolimus	1	1	8
Cabozantinib	1	0	3
Olaparib	1	0	1
Pasireotide	0	1	4
Paltusotine	0	1	2
Nivolumab	0	0	2
Lanreotide	0	1	2
Ganitumab	0	0	2
Capecitabine	0	0	2
Temozolomide	0	0	2

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 1 open · Immune checkpoint inhibitors 4 · Angiogenesis inhibitors 4 · Antimitotic agents 3 · Alkylating agents 3

Coming up

3phase 3 studies under way

9studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 9, phase 3 first

Dec 2026Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy · Phase 3 · RayzeBio, Inc.
Aug 2027Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen · Phase 3 · Crinetics Pharmaceuticals Inc.
Dec 2026Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors · Fox Chase Cancer Center
Dec 2026An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors · M.D. Anderson Cancer Center
Feb 2027Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. · RayzeBio, Inc.
Mar 2027Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes · Cedars-Sinai Medical Center
May 2027Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) · Merck Sharp & Dohme LLC
Jun 2027ALG-LungCancerRegistry (SAFRO2202) · Société Algérienne de Formation et de Recherche en Oncologie
Jul 2027Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) · National Cancer Institute (NCI)

Who these studies take

Of the 10 Carcinoid Tumor studies recruiting now, 7 (70%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (10%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 10
Age	Women	Men
10	0 (0%)	0 (0%)
18	10 (100%)	10 (100%)
30	10 (100%)	10 (100%)
40	10 (100%)	10 (100%)
50	10 (100%)	10 (100%)
65	10 (100%)	10 (100%)
75	10 (100%)	10 (100%)
85	10 (100%)	10 (100%)

Across all 104 studies, recruiting or not: 1% stop at 75 or younger and 0% at 65; 13% take children; 0% are for women only and 0% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Carcinoid Tumor studies take

Of 19 phase 2 interventional studies under Carcinoid Tumor, half reached primary completion within 70 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 2	70 mo52–107 · 19 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Started recruiting1

Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine NeoplasmsNov 6, 2026NCT07842172

Studies

Recruiting first, then most recently updated. Showing 50 of 104. Browse all 104 → or search them.